To access this material please log in or register

Register Authorize

Acetylsalicylic acid resistance: Causes and effects

Buryachkovskaya L. I.1, Lomakin N. V.2, Rusanova A. V.3, Vershinina M. G.2
1 – Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552
2 – Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Clinic" at the Department of Presidential Affairs, Marshala Timoshenko 15, Moscow 121359
3 – Federal State Budgetary Institution "Educational and Scientific Medical Center" at the Department of Presidential Affairs, Marshala Timoshenko 19, Bldg. 1а, Moscow 121359

Keywords: antiaggregates, acetylsalicylic acid, ischaemic heart disease, different dosage forms, salicylic acid, platelets

DOI: 10.18087/rhj.2016.5.2261

Acetylsalicylic acid (ASA) is a basement of current antiplatelet therapy. Since the early 80s of the 20th century, ASA has been actively used in clinical practice for prevention of thrombotic complications of therapy for ACS and MI, IHD, and peripheral atherosclerosis, TIA and ischemic stroke and other cardiovascular conditions. The antiplatelet efficacy of ASA has been confirmed by numerous studies. However, there is much evidence that, despite the ASA treatment, this drug does on provide an adequate effect on platelet activity and may be associated with thrombotic events. This phenomenon was named ASA “resistance”. At the same time, intravenous administration of ASA solution is known to depress platelet aggregation and TXA 2 synthesis always. The article focuses on effects of different ASA tablet forms on this phenomenon and provides evidence of ASA tablets efficacy in patients with stable IHD and diabetes or CHF.
  1. Gibson PC. Salicylic acid for coronary thrombosis? Lancet. 1948 Jun 19;1 (6512):965.
  2. Gibson PC. Aspirin in the treatment of vascular diseases. Lancet. 1949 Dec 24;2 (6591):1172–4.
  3. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956 Sep;78 (5):213–5.
  4. Ferreira SH, Moncada S, Vane JR. Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol. 1973 Sep;49 (1):86–97.
  5. A randomized trial of aspirin and sulfinpyrazone in threatened stroke: the Canadian Cooperative Study Group. N Engl J Med. 1978 Jul 13;299 (2):53–9.
  6. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313 (22):1369–75.
  7. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011 Feb 22;123 (7):768–78.
  8. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373 (9678):1849–60.
  9. Williams SE, Floyd CN, Marber M. The changing face of acute coronary syndromes. Heart Metab. 2011;50:9–14.
  10. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006 Dec;319 (3):1467–76.
  11. Rowland M, Riegelman S. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci. 1968;57:1313–9.
  12. Schwer H, Langmann T, Daig R, Becker A, Aslanidis C, Schmitz G. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun. 1997 Apr 7;233 (1):117–20.
  13. Redinbo MR, Bencharit S, Potter PM. Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003 Jul;31 (Pt 3):620–4.
  14. Costello PB, Green FA. Aspirin survival in human blood modulated by the concentration of erythrocytes. Arthritis Rheum. 1982 May;25 (5):550–5.
  15. de Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation. 1985 Dec;72 (6):1185–93.
  16. Kees F, Jehnich D, Grobecker H. Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by highperformance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 23;677 (1):172–7.
  17. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol. 1982 May;76 (1):3–31.
  18. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 Nov 8;311 (19):1206–11.
  19. Rumble RH, Brooks PM, Roberts MS. Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol. 1980 Jan;9 (1):41–5.
  20. Jung JA, Kim TE, Kim JR, Kim MJ, Huh W, Park KM et al. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2‑sequence, 2‑period, single-dose crossover study. Clin Ther. 2013 Jul;35 (7):985–94.
  21. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin‐induced gastric mucosal damage: prevention by enteric‐coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991 Jul;32 (1):77–83.
  22. Paterson JR, Baxter G, Dreyer JS, Halket JM, Flynn R, Lawrence JR. Salicylic acid sans aspirin in animals and man: persistence in fasting and biosynthesis from benzoic acid. J Agric Food Chem. 2008 Dec 24;56 (24):11648–52.
  23. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006 Feb 18;367 (9510):606–17.
  24. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 Jan 26;336 (7637):195–8.
  25. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005 Apr 15;95 (8):973–5.
  26. Gencheva E, Sloan M, Leurgans S, Raman R, Harris Y, Gorelick P. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology. 2004 Jan-Apr;23 (1-2):61–6.
  27. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance: detection by TEG platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005 Nov 1;46 (9):1705–9.
  28. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994 Feb 15;83 (4):885–98.
  29. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007 Jun 26;115 (25):3156–64.
  30. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014 Jan;141 (1):69–78.
  31. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002 Jul 15;107 (1):45–9.
  32. Böger RH, Bode-Böger SM, Gutzki FM, Tsikas D, Weskott HP, Frolich JC. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci (Lond). 1993 May;84 (5):517–24.
  33. Vivas D, Martín A, Bernardo E, Ortega-Pozzi M, Tirado G, Fernandez C et al. Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial). Circ Cardiovasc Interv. 2015 May;8 (5).pii:e002281.
  34. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006 Aug;37 (8):2153–8.
  35. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006 Mar;27 (6):647–54.
  36. Santilli F, Pignatelli P, Violi F, Davì G. Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk / benefit profile to personalised treatment. Thromb Haemost. 2015 Nov;114 (5):876–82.
  37. Grimaldi R, Bisi M, Lonni E, Beggiato E, Valpreda A, Lococo MF et al. Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations. Cardiovasc Drugs Ther. 2014 Aug;28 (4):323–9.
  38. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996 Nov 23;348 (9039):1413–6.
  39. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin induced gastric mucosal damage: prevention by enteric coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991 Jul;32 (1):77–83.
  40. Ivey KJ, Paone DB, Krause WJ. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci. 1980 Feb;25 (2):97–9.
  41. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA et al. 2016 ACC / AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF / AHA / SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF / AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF / AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA / ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC / AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6;134 (10):e123–55.
  42. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001 Nov;52 (5):563–71.
  43. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999 Jul;117 (1):17–25.
  44. Ломакин Н. В., Русанова А. В., Бурячковская Л. И., Вершинина М. Г. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце. 2014;13 (4):206–15 [Lomakin N. V., Rusanova A. V., Buryachkovskaya L. I., Vershinina M. G. Sravnenie antiagregantnoj e`ffektivnosti razny`x form aczetilsaliczilovoj kisloty`. Serdcze. 2014;13 (4):206–15].
  45. Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P et al. Platelet Function Testing by Aggregometry; Approved Guideline. CLSI. 2008; H58‑A;28 (31):1–60.
  46. Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC / ISTH. J Thromb Haemost. 2013 Apr 10;11 (6):1183–9.
  47. Ивашкин B. Т., Шептулин А. А. Синдром диареи. – М.: «ГЭОТАР-Медиа», 2000. – 135с [Ivashkin B. T., Sheptulin A. A. Sindrom diarei. – M.: «GE`OTAR-Media», 2000. – 135s].
  48. Abel RM, Fischer JE, Buckley MJ, Barnett GO, Austen WG. Malnutricion in cardiac surgical patients. Results of a prospective, randomized evalution of early postoperative parenteral nutrition. Arch Surg. 1976 Jan;111 (1):45–50.
  49. Чубирко И. Е., Провоторов В. М., Чубирко Ю. М. Исследование мальабсорбции у больных ишемической болезнью сердца и хронической обструктивной болезнью легких с фибрилляцией предсердий. Актуальные проблемы гуманитарных и естественных наук. 2013;12–2:344–7 [Chubirko I. E., Provotorov V. M., Chubirko Yu. M. Issledovanie mal`absorbczii u bol`ny`x ishemicheskoj bolezn`yu serdcza i xronicheskoj obstruktivnoj bolezn`yu legkix s fibrillyacziej predserdij. Aktual`ny`e problemy` gumanitarny`x i estestvenny`x nauk. 2013;12–2:344–7].
Buryachkovskaya L. I., Lomakin N. V., Rusanova A. V., Vershinina M. G. Acetylsalicylic acid resistance: Causes and effects. Russian Heart Journal. 2016;15 (5):379–388

To access this material please log in or register

Register Authorize
Ru En